Predictive and prognostic markers in human glioblastomas

Current Treatment Options in Oncology

Volumn 7, Issue 6, 2006, Pages 490-504

  Palanichamy, Kamalakannan ^a   Erkkinen, Michael ^a   Chakravarti, Arnab ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADENOSINE TRIPHOSPHATE; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CILENGITIDE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; IRINOTECAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TEMOZOLOMIDE; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VATALANIB;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FATIGUE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; LIVER DYSFUNCTION; METHYLATION; MOLECULAR BIOLOGY; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; RASH; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT OUTCOME; VALIDATION PROCESS;

CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750741410     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0024-7     Document Type: Review

References (40)

1. Maher EA, Furnari FB, Bachoo RM, et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001, 15:1311-1333.
2. Geng L, Shinohara ET, Kim D, et al.: STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 2006, 64:263-271.
3. Hagerstrand D, Hesselager G, Achterberg S, et al.: Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 2006, In press.
4. Reardon DA, Egorin MJ, Quinn JA, et al.: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005, 23:9359-9368.
5. Frederick L, Wang XY, Eley G, James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000, 60:1383-1387.
6. Chakravarti A, Seiferheld W, Tu X, et al.: Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005, 62:318-327.
7. Miettinen PJ, Berger JE, Meneses J, et al.: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376:337-341.
8. Threadgill DW, Dlugosz AA, Hansen LA et al.: Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995, 269:230-234.
9. Burrows RC, Wancio D, Levitt P, Lillien L: Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex. Neuron 1997, 19:251-267.
10. Fricker-Gates RA, Winkler C, Kirik D, et al.: EGF infusion stimulates the proliferation and migration of embryonic progenitor cells transplanted in the adult rat striatum. Exp Neurol 2000, 165:237-247.
11. Barker FG 2nd, Simmons ML, Chang SM, et al.: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 51:410-418.
12. Chakravarti A, Delaney MA, Noll E, et al.: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001, 7:2387-2395.
13. Etienne MC, Formento JL, Lebrun-Frenay C, et al.: Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998, 4:2383-2390.
14. Feldkamp MM, Lala P, Lau N, et al.: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999, 45:1442-1453.
15. Shinojima N, Tada K, Shiraishi S, et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63:6962-6970.
16. Smith JS, Tachibana I, Passe SM, et al.: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93:1246-1256.
17. Rainov NG, Dobberstein KU, Bahn H, et al.: Prognostic factors in malignant glioma: influence of the over-expression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 1997, 35:13-28.
18. Chakravarti A, Seiferheld W, Tu X, et al.: Immunohistochemically determined total EGFR levels not of prognostic value in newly diagnosed GBM: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005, 62:318-327.
19. Buckner JC, Aldape KD, Ballman K et al.: Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. J Clin Oncol 2004, 22(Suppl 14):1508.
20. Prados M, Yung W, Wen P, et al.: Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. J Clin Oncol 2004, 22(Suppl 14):1504.
21. Rich JN, Reardon DA, Peery T, et al.: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
22. Prados M, Chang S, Burton E, et al.: Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc Am Soc Clin Oncol 2003, 22:99.
23. Chakravarti A, Zhai G, Suzuki Y, et al.: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004, 22:1926-1933.
24. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
25. Chakravarti A, Seiferheld W, Robins HI, et al.: An update of phase I data from RTOG 0211: a phase I/II clinical study of gefitinib+radiation for newly-diagnosed GBM patients. J Clin Oncol 2004, 22(Suppl 14):1571.
26. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000, 92:1472-1489.
27. Chakravarti A, Chakladar A, Delaney MA, et al.: The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002, 62:4307-4315.
28. Andrews DW, Resnicoff M, Flanders AE, et al.: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001, 19:2189-2200.
29. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
30. Guha A: Ras activation in astrocytomas and neurofibromas. Can J Neurol Sci 1998, 25:267-281.
31. Feldkamp MM, Lau N, Roncari L, Guha A: Isotype-specific Ras. GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 2001, 61:4425-4431.
32. Ding H, Roncari L, Shannon P, et al.: Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001, 61:3826-3836.
33. Zagzag D, Amirnovin R, Greco MA, et al.: Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 2000, 80:837-849.
34. Zagzag D, Salnikow K, Chiriboga L, et al.: Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 2005, 85:328-341.
35. Brat DJ, Van Meir EG: Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004, 84:397-405.
36. Rong Y, Post DE, Pieper RO, et al.: PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005, 65:1406-1413.
37. Pope WB, Lai A, Nghiemphu P, et al.: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66:1258-1260.
38. Hegi ME, Diserens AC, Gorlia T et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
39. Zhang M, Chakravarti A: Novel radiation-enhancing agents in malignant gliomas. Semin Radiat Oncol 2006, 16:29-37.
40. Chakravarti A, Erkkinen MG, Nestler U, et al.: Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006, 12:4738-4746.